Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial

Matthias Griese; Stefano Costa; Rachel W. Linnemann; Marcus A. Mall; Edward F. McKone; Deepika Polineni; Bradley S. Quon; Felix C. Ringshausen; Jennifer L. Taylor-Cousar; Nicholas J. Withers; Samuel M. Moskowitz; Cori L. Daines

doi:10.1164/rccm.202008-3176LE

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial

Matthias Griese
, Stefano Costa
, Rachel W. Linnemann
, Marcus A. Mall
, Edward F. McKone
, Deepika Polineni
, Bradley S. Quon
, Felix C. Ringshausen
, Jennifer L. Taylor-Cousar
, Nicholas J. Withers
, Samuel M. Moskowitz
, Cori L. Daines

Division of Allergy & Pulmonary Medicine

Research output: Contribution to journal › Letter › peer-review

152 Scopus citations

Original language	English
Pages (from-to)	381-385
Number of pages	5
Journal	American journal of respiratory and critical care medicine
Volume	203
Issue number	3
DOIs	https://doi.org/10.1164/rccm.202008-3176LE
State	Published - Feb 1 2021

Access to Document

10.1164/rccm.202008-3176LE

Cite this

Griese, M., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Taylor-Cousar, J. L., Withers, N. J., Moskowitz, S. M., & Daines, C. L. (2021). Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. American journal of respiratory and critical care medicine, 203(3), 381-385. https://doi.org/10.1164/rccm.202008-3176LE

@article{ab6bbe6f4c3f43db8177a867dc3c943c,

title = "Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial",

author = "Matthias Griese and Stefano Costa and Linnemann, \{Rachel W.\} and Mall, \{Marcus A.\} and McKone, \{Edward F.\} and Deepika Polineni and Quon, \{Bradley S.\} and Ringshausen, \{Felix C.\} and Taylor-Cousar, \{Jennifer L.\} and Withers, \{Nicholas J.\} and Moskowitz, \{Samuel M.\} and Daines, \{Cori L.\}",

note = "Funding Information: Supported by research grants from the Ministry of Health, Labor and Welfare of Japan (201706009A) and the Advanced Research and Development Programs for Medical Innovation (18lk1403023h0001 and Advanced Research and Development Programs for Medical Innovation-Core Research for Evolutional Science and Technology; 16 gm1010003h0001).",

year = "2021",

month = feb,

day = "1",

doi = "10.1164/rccm.202008-3176LE",

language = "English",

volume = "203",

pages = "381--385",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

number = "3",

}

Griese, M, Costa, S, Linnemann, RW, Mall, MA, McKone, EF, Polineni, D, Quon, BS, Ringshausen, FC, Taylor-Cousar, JL, Withers, NJ, Moskowitz, SM & Daines, CL 2021, 'Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial', American journal of respiratory and critical care medicine, vol. 203, no. 3, pp. 381-385. https://doi.org/10.1164/rccm.202008-3176LE

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. / Griese, Matthias; Costa, Stefano; Linnemann, Rachel W. et al.
In: American journal of respiratory and critical care medicine, Vol. 203, No. 3, 01.02.2021, p. 381-385.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles

T2 - Interim results of an open-label phase 3 clinical trial

AU - Griese, Matthias

AU - Costa, Stefano

AU - Linnemann, Rachel W.

AU - Mall, Marcus A.

AU - McKone, Edward F.

AU - Polineni, Deepika

AU - Quon, Bradley S.

AU - Ringshausen, Felix C.

AU - Taylor-Cousar, Jennifer L.

AU - Withers, Nicholas J.

AU - Moskowitz, Samuel M.

AU - Daines, Cori L.

N1 - Funding Information: Supported by research grants from the Ministry of Health, Labor and Welfare of Japan (201706009A) and the Advanced Research and Development Programs for Medical Innovation (18lk1403023h0001 and Advanced Research and Development Programs for Medical Innovation-Core Research for Evolutional Science and Technology; 16 gm1010003h0001).

PY - 2021/2/1

Y1 - 2021/2/1

UR - https://www.scopus.com/pages/publications/85096144059

U2 - 10.1164/rccm.202008-3176LE

DO - 10.1164/rccm.202008-3176LE

M3 - Letter

C2 - 32969708

AN - SCOPUS:85096144059

SN - 1073-449X

VL - 203

SP - 381

EP - 385

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 3

ER -

Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. American journal of respiratory and critical care medicine. 2021 Feb 1;203(3):381-385. doi: 10.1164/rccm.202008-3176LE

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial

Access to Document

Other files and links

Cite this